Effects of CYP3A5 polymorphism and the tacrolimus 12 h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis

被引:1
作者
Niioka, Takenori [1 ]
Komatsuda, Atsushi [2 ]
Kato, Shotaro [1 ]
Togashi, Masaru [2 ]
Okuyama, Shin [3 ]
Omokawa, Ayumi [4 ]
Nara, Mizuho [2 ]
Wakui, Hideki [5 ]
Takahashi, Naoto [2 ]
Miura, Masatomo [1 ]
机构
[1] Akita Univ Hosp, Dept Pharm, Akita, Japan
[2] Akita Univ, Grad Sch Med, Dept Hematol, Nephrol,Rheumatol, 1-1-1 Hondo, Akita 0108543, Japan
[3] Akita Univ Hosp, Ctr Kidney Dis & Transplantat, Akita, Japan
[4] Akita Univ, Grad Sch Med, Dept Gen Internal Med & Clin Lab Med, Akita 0108543, Japan
[5] Akita Univ, Grad Sch Engn & Resource Sci, Dept Life Sci, Akita 0108543, Japan
基金
日本学术振兴会;
关键词
Acute renal dysfunction; CYP3A5; polymorphism; lupus nephritis; tacrolimus; therapeutic drug monitoring; SINGLE NUCLEOTIDE POLYMORPHISMS; PRIMARY KIDNEY-TRANSPLANTATION; SOLID-ORGAN TRANSPLANTATION; JAPANESE POPULATION; OPEN-LABEL; PHARMACOKINETICS; FK506; TRIAL; PHARMACODYNAMICS; EFFICACY;
D O I
10.3109/00498254.2015.1045571
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The purpose of the present study was to investigate the effect of tacrolimus concentration in blood 12 h after administration (C-12h) on acute renal dysfunction in patients with lupus nephritis (LN) taking tacrolimus once daily. 2. Five of the 35 LN patients experienced tacrolimus-induced acute renal dysfunction. 3. The average annual C-12h of tacrolimus was higher for patients with events of elevated serum creatinine level than for patients not experiencing these events [6.4 (5.6-8.8) versus 2.8 (2.2-4.6) ng/mL, respectively, p = 0.001]. 4. The average annual tacrolimus C-12h was higher for patients with CYP3A5*3/*3 (PM) than for patients with the CYP3A5*1 allele (EM) [4.6 (3.2-6.6) versus 2.5 (2.0-3.1) ng/mL, respectively, p = 0.002]. 5. The area under the receiver operating characteristic was 0.887, which gave the best sensitivity (80.0%) and specificity (86.7%) at a tacrolimus C-12h (average annual C-12h or C-12h at events) threshold of 5.2 ng/mL. 6. C-12h measurements, CYP3A5 genotyping and dose adjustments of tacrolimus should be performed to prevent acute renal dysfunction in LN patients taking tacrolimus once daily.
引用
收藏
页码:1147 / 1153
页数:7
相关论文
共 33 条
[1]   Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial [J].
Chen, W. ;
Liu, Q. ;
Chen, W. ;
Tang, X. ;
Fu, P. ;
Liu, F. ;
Liao, Y. ;
Yang, Z. ;
Zhang, J. ;
Chen, J. ;
Lou, T. ;
Fu, J. ;
Kong, Y. ;
Liu, Z. ;
Li, Z. ;
Yu, X. .
LUPUS, 2012, 21 (09) :944-952
[2]   Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial [J].
Chen, Wei ;
Tang, Xueqing ;
Liu, Qinghua ;
Chen, Weiying ;
Fu, Ping ;
Liu, Fang ;
Liao, Yunhua ;
Yang, Zhenhua ;
Zhang, Jinli ;
Chen, Jian ;
Lou, Tanqi ;
Fu, Junzhou ;
Kong, Yaozhong ;
Liu, Zhengrong ;
Fan, An ;
Rao, Shaoqi ;
Li, Zhibin ;
Yu, Xueqing .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (02) :235-244
[3]   Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods [J].
De, Barun K. ;
Jimenez, E. ;
De, S. ;
Sawyer, J. C. ;
McMillin, G. A. .
CLINICA CHIMICA ACTA, 2009, 410 (1-2) :25-30
[4]   Cardiovascular risk factors and the long-term outcome of lupus nephritis [J].
Font, J ;
Ramos-Casals, M ;
Cervera, R ;
García-Carrasco, M ;
Torras, A ;
Sisó, A ;
Darnell, A ;
Ingelmo, M .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (01) :19-26
[5]   Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population [J].
Fukuen, S ;
Fukuda, T ;
Maune, H ;
Ikenaga, Y ;
Yamamoto, I ;
Inaba, T ;
Azuma, J .
PHARMACOGENETICS, 2002, 12 (04) :331-334
[6]  
Haehner BD, 1996, MOL PHARMACOL, V50, P52
[7]   The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation [J].
Hesselink, Dennis A. ;
Bouamar, Rachida ;
Elens, Laure ;
van Schaik, Ron H. N. ;
van Gelder, Teun .
CLINICAL PHARMACOKINETICS, 2014, 53 (02) :123-139
[8]   Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus [J].
Hirai, Fumihito ;
Takatsu, Noritaka ;
Yano, Yutaka ;
Satou, Yuhou ;
Takahashi, Haruhiko ;
Ishikawa, Satoshi ;
Tsurumi, Kozue ;
Hisabe, Takashi ;
Matsui, Toshiyuki .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (01) :60-66
[9]   Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population [J].
Hiratsuka, M ;
Takekuma, Y ;
Endo, N ;
Narahara, K ;
Hamdy, SI ;
Kishikawa, Y ;
Matsuura, M ;
Agatsuma, Y ;
Inoue, T ;
Mizugaki, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (06) :417-421
[10]   Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation [J].
Kershner, RP ;
Fitzsimmons, WE .
TRANSPLANTATION, 1996, 62 (07) :920-926